Salvage robotic prostatectomy for radio recurrent prostate cancer: technical challenges and outcome analysis

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorZARGAR, Homayoun
dc.contributor.authorLAMB, Alastair D.
dc.contributor.authorROCCO, Bernardo
dc.contributor.authorPORPIGLIA, Francesco
dc.contributor.authorLIATSIKOS, Evangelos
dc.contributor.authorDAVIS, John
dc.contributor.authorCOELHO, Rafael F.
dc.contributor.authorPOW-SANG, Julio M.
dc.contributor.authorPATEL, Vipul R.
dc.contributor.authorMURPHY, Declan G.
dc.date.accessioned2017-06-09T15:38:28Z
dc.date.available2017-06-09T15:38:28Z
dc.date.issued2017
dc.description.abstractINTRODUCTION: The published data on salvage robot assisted radical prostatectomy (sRARP) is limited. Our aim was to perform a systematic review of the literature on sRARP after radiation failure in patients with prostate cancer and systematically analyse the available evidence for operative and oncological outcomes. EVIDENCE ACQUISITION: A systematic review of the literature using Pubmed, Scopus, Cochrane library and ScienceDirect databases was performed in June 2016 using medical subject headings and free-text protocol. The search was conducted by applying the following search terms: salvage therapy, salvage, prostatectomy and robotics. EVIDENCE SYNTHESIS: We report on ten case series including 197 men undergoing sRARP after varying modalities of radiotherapy. Over two thirds are recurrence free at the time of follow-up but with continence rates of only 60% and potency rates of only 26%. Complications requiring intervention are few at 16% though higher than primary RARP. CONCLUSIONS: sRARP is increasingly acceptable as a treatment modality to be offered to men who fail initial radiation treatment but should be accompanied by appropriate counselling regarding the potential functional outcomes and complications. Series with longer follow-up will be helpful to assess the durability of oncological outcomes while improvements in patient selection and adaption of meticulous surgical technique around the apex could improve continence rates. The concept of concomitant extended PLND remains an issue for debate and the experience with this approach at the time of sRARP and its benefit need further scrutiny.
dc.description.indexMEDLINE
dc.description.sponsorshipProstate Cancer UK [PA14-022]
dc.identifier.citationMINERVA UROLOGICA E NEFROLOGICA, v.69, n.1, p.26-37, 2017
dc.identifier.doi10.23736/S0393-2249.16.02797-1
dc.identifier.eissn1827-1758
dc.identifier.issn0393-2249
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/20206
dc.language.isoeng
dc.publisherEDIZIONI MINERVA MEDICA
dc.relation.ispartofMinerva Urologica e Nefrologica
dc.rightsrestrictedAccess
dc.rights.holderCopyright EDIZIONI MINERVA MEDICA
dc.subjectProstatectomy
dc.subjectSurgery, computer-assisted
dc.subjectProstatic neoplasms
dc.subjectBiochemical processes
dc.subjectRadiotherapy
dc.subject.otherexternal-beam radiotherapy
dc.subject.otherterm functional outcomes
dc.subject.othersingle-institution
dc.subject.otherradiation failure
dc.subject.otherrisk
dc.subject.otheradenocarcinoma
dc.subject.otherexperience
dc.subject.othersurvival
dc.subject.otherbiopsies
dc.subject.othertherapy
dc.subject.wosUrology & Nephrology
dc.titleSalvage robotic prostatectomy for radio recurrent prostate cancer: technical challenges and outcome analysis
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryGrécia
hcfmusp.affiliation.countryAustrália
hcfmusp.affiliation.countryisoau
hcfmusp.affiliation.countryisoit
hcfmusp.affiliation.countryisogr
hcfmusp.affiliation.countryisous
hcfmusp.author.externalZARGAR, Homayoun:Royal Melbourne Hosp, Dept Surg, Div Urol, Grattan St, Parkville, Vic, Australia; Univ Melbourne, Grattan St, Parkville, Vic, Australia; Epworth Healthcare, Australian Prostate Canc Res Ctr, Richmond, Vic, Australia
hcfmusp.author.externalLAMB, Alastair D.:Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
hcfmusp.author.externalROCCO, Bernardo:European Inst Urol, Milan, Italy
hcfmusp.author.externalPORPIGLIA, Francesco:San Luigi Gonzaga Hosp, Sch Med, Dept Urol, Orbassano, Italy
hcfmusp.author.externalLIATSIKOS, Evangelos:Univ Patras, Patras, Greece
hcfmusp.author.externalDAVIS, John:Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA
hcfmusp.author.externalPOW-SANG, Julio M.:H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
hcfmusp.author.externalPATEL, Vipul R.:Univ Cent Florida, Coll Med, Florida Hosp Celebrat Hlth, Global Robot Inst, Orlando, FL 32816 USA
hcfmusp.author.externalMURPHY, Declan G.:Epworth Healthcare, Australian Prostate Canc Res Ctr, Richmond, Vic, Australia; Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
hcfmusp.citation.scopus35
hcfmusp.contributor.author-fmusphcRAFAEL FERREIRA COELHO
hcfmusp.description.beginpage26
hcfmusp.description.endpage37
hcfmusp.description.issue1
hcfmusp.description.volume69
hcfmusp.origemWOS
hcfmusp.origem.pubmed27579821
hcfmusp.origem.scopus2-s2.0-85014459246
hcfmusp.origem.wosWOS:000397991100004
hcfmusp.publisher.cityTURIN
hcfmusp.publisher.countryITALY
hcfmusp.relation.referenceAbdollah F, 2015, EUR UROL, V67, P212, DOI 10.1016/j.eururo.2014.05.011
hcfmusp.relation.referenceAbdul-Muhsin H, 2013, BJU INT, V111, P686, DOI 10.1111/bju.12073
hcfmusp.relation.referenceBates AS, 2015, EJSO-EUR J SURG ONC, V41, P1540, DOI 10.1016/j.ejso.2015.06.002
hcfmusp.relation.referenceBolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0
hcfmusp.relation.referenceBoris RS, 2009, BJU INT, V103, P952, DOI 10.1111/j.1464-410X.2008.08245.x
hcfmusp.relation.referenceChade DC, 2012, EUR UROL, V61, P961, DOI 10.1016/j.eururo.2012.01.022
hcfmusp.relation.referenceChauhan S, 2011, J ENDOUROL, V25, P1013, DOI 10.1089/end.2010.0564
hcfmusp.relation.referenceCox JD, 1997, INT J RADIAT ONCOL, V37, P1035
hcfmusp.relation.referenceCrook J, 2000, INT J RADIAT ONCOL, V48, P355, DOI 10.1016/S0360-3016(00)00637-4
hcfmusp.relation.referenceCrook JM, 2009, CANCER, V115, P673, DOI 10.1002/cncr.24020
hcfmusp.relation.referenceD'Amico AV, 2005, J CLIN ONCOL, V23, P4975, DOI 10.1200/JCO.2005.08.904
hcfmusp.relation.referenceEandi JA, 2010, J UROLOGY, V183, P133, DOI 10.1016/j.juro.2009.08.134
hcfmusp.relation.referenceGabriele D, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0599-5
hcfmusp.relation.referenceGnanapragasam VJ, 2016, BJU INT
hcfmusp.relation.referenceHerlemann A, 2016, EUR UROL
hcfmusp.relation.referenceJamal K, 2008, UROLOGY, V72, P1356, DOI 10.1016/j.urology.2008.04.007
hcfmusp.relation.referenceKaffenberger SD, 2013, J UROLOGY, V189, P507, DOI 10.1016/j.juro.2012.09.057
hcfmusp.relation.referenceKaouk JH, 2008, BJU INT, V102, P93, DOI 10.1111/j.1464-410X.2008.07570.x
hcfmusp.relation.referenceKumar AMS, 2015, J CONTEMP BRACHYTHER, V7, P241, DOI 10.5114/jcb.2015.54050
hcfmusp.relation.referenceMatei DV, 2015, UROL INT, V94, P373, DOI 10.1159/000371893
hcfmusp.relation.referenceMateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859
hcfmusp.relation.referenceMaurer T, 2016, NAT REV UROL, V13, P226, DOI 10.1038/nrurol.2016.26
hcfmusp.relation.referenceMoher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
hcfmusp.relation.referenceMoschini M, 2016, EUR UROL, V69, P193, DOI 10.1016/j.eururo.2015.07.047
hcfmusp.relation.referenceNEERHUT GJ, 1988, J UROLOGY, V140, P544
hcfmusp.relation.referenceNovara G, 2010, EUR UROL, V57, P363, DOI 10.1016/j.eururo.2009.11.032
hcfmusp.relation.reference[Anonymous], 2009, LEVELS EVIDENCE
hcfmusp.relation.referencePerera M, 2016, EUR UROL
hcfmusp.relation.referencePetraki CD, 2007, HISTOL HISTOPATHOL, V22, P107, DOI 10.14670/HH-22.107
hcfmusp.relation.referenceRoach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029
hcfmusp.relation.referenceRocco B, 2012, CURR UROL REP, V13, P195, DOI 10.1007/s11934-012-0245-1
hcfmusp.relation.referenceSooriakumaran P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1502
hcfmusp.relation.referenceStrope SA, 2010, J ENDOUROL, V24, P425, DOI 10.1089/end.2009.0143
hcfmusp.relation.referenceVallancien G, 2003, J UROLOGY, V170, P1838, DOI 10.1097/01.ju.0000091875.24816.6b
hcfmusp.relation.referencevan Leeuwen PJ, 2016, BJU INT
hcfmusp.relation.referenceVora A, 2016, PROSTATE INT, V4, P7, DOI 10.1016/j.prnil.2015.11.002
hcfmusp.relation.referenceYuh B, 2014, BJU INT, V113, P769, DOI 10.1111/bju.12595
hcfmusp.relation.referenceZugor V, 2014, UROL INT, V92, P20, DOI 10.1159/000351948
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication08a6127c-2951-4cc6-b1dc-2a251aa15691
relation.isAuthorOfPublication.latestForDiscovery08a6127c-2951-4cc6-b1dc-2a251aa15691
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_ZARGAR_Salvage_robotic_prostatectomy_for_radio_recurrent_prostate_cancer_2017.PDF
Tamanho:
1.9 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03